Brief: CTI Biopharma Initiates Rolling Submission Of NDA For Pacritinib
13/10/2020 12:12
Oct 13 (Reuters) - CTI Biopharma Corp CTIC.O :
* CTI BIOPHARMA INITIATES ROLLING SUBMISSION OF NEW DRUG
APPLICATION (NDA) FOR PACRITINIB IN MYELOFIBROSIS PATIENTS WITH
SEVERE THROMBOCYTOPENIA
* CTI BIOPHARMA CORP - COMPLETION OF SUBMISSION EXPECTED IN
Q1
2021
Source text for Eikon: ID:nPn7zBHzha
Further company coverage: CTIC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CTI Biopharma
See all newsBrief: CTI Biopharma Cancels 2023 Annual Meeting Of Stockholders
U.S. RESEARCH ROUNDUP-Albemarle, Ellington Financial, Savara
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
U.S. STOCKS ON THE MOVE-First Citizens BancShares, Sarepta, Celsius Holdings
U.S. STOCKS ON THE MOVE-Taboola, US banks, Copper miners